SBC

Business Context and Reporting Period

Company: SBC Medical Group Holdings Inc (SBC)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: SBC is a management company headquartered in Irvine, California, and Tokyo, Japan. It provides comprehensive management services to cosmetic treatment centers, primarily in Japan (241 franchisee clinics), with operations also in Vietnam, Singapore, and the United States. Services include marketing, staffing, procurement, IT solutions, and licensing of medical technologies.
Recent Corporate Actions:

• Completed a reverse recapitalization (Business Combination) with Pono Capital Two, Inc. on September 17, 2024.
• Acquired 100% of Aesthetic Healthcare Holdings (AHH) in Singapore for approximately $5.8 million in November 2024.
• Disposed of subsidiaries Kijimadairakanko Inc. and Skynet Academy Co., Ltd. to entities controlled by the CEO in December 2024.

Key Financial Metrics

Note: The filing text does not provide a specific total debt figure, but lists long-term loans of approximately $6.6 million and notes payable to related parties of approximately $31.6 million as of December 31, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 6.1% to $205.4 million. This was driven by a 45.0% increase in Franchising Revenue ($61.0M) and a 120.0% increase in Rental Services Revenue ($16.1M), partially offset by a 26.5% decrease in Management Services Revenue ($53.1M) due to the discontinuation of certain staff support services and a reduction in loyalty program handling fees.
• Profitability: Net income increased 21.1% to $46.7 million. Gross margin improved to 76.0% from 70.9% due to cost reduction efforts and the shift in revenue mix toward higher-margin franchising fees.
• Operating Expenses: Increased 28.7% to $85.7 million. This increase was primarily due to a one-time $15.1 million impairment loss on an intangible asset (patent use right) and $13.0 million in stock-based compensation related to warrants issued for listing services. These were partially offset by a significant decrease in depreciation and amortization expenses.
• Cash Flow: Operating cash flow decreased significantly by 59.4% to $20.6 million, largely due to changes in working capital, specifically a decrease in notes payable to related parties and finance lease receivables.
• Foreign Exchange: The depreciation of the Japanese Yen against the U.S. Dollar had an unfavorable impact of approximately $16.0 million on net revenues and $3.5 million on net income.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

Management plans to revise its fee structure for newly opened clinics effective April 2025 to reduce initial costs for franchisees, transitioning to a performance-based model in the second year. While this may reduce revenue by approximately 10% if applied retroactively, management expects the impact to be offset in 2025 by the absence of one-time 2024 losses (impairment and stock-based compensation). The company expects to generate a gain of approximately $9.3 million in Q1 2025 from the maturity of corporate-owned life insurance policies.

Unusual Items

• Misappropriation of Funds: In January 2024, a former director of a subsidiary was found to have misappropriated approximately $5.6 million (JPY 632 million) through kickbacks from vendors. A criminal complaint was filed. A misappropriation loss of $409,030 was recorded in 2023; no loss was recorded in 2024 as the amounts were reclassified from revenue.
• Impairment Loss: A one-time impairment loss of $15.1 million was recognized on a patent use right intangible asset in 2024.
• Stock-Based Compensation: $13.0 million in stock-based compensation was recognized in 2024 related to warrants issued to a service provider for the listing process.

Material Risks

• Internal Controls: The company identified material weaknesses in internal controls over financial reporting as of December 31, 2024, related to the misappropriation of funds. These include deficiencies in the control environment, risk assessment, and monitoring activities. Remediation is ongoing, with a target completion of key financial reporting risk responses by the end of 2025.
• Related Party Concentration: Over 90% of revenue is derived from related-party Medical Corporations (MCs). The CEO's family members hold significant voting power in these MCs.
• Regulatory and Legal: Risks include compliance with medical care acts in Japan, Vietnam, and Singapore, as well as potential product liability claims (for which the company has limited insurance coverage).
• Delisting Risk: The company faces risks regarding maintaining Nasdaq listing requirements, including public float and stock price levels.

Investor Verification Checklist

• Internal Control Remediation: Verify the progress of the remediation plan for material weaknesses in internal controls, specifically regarding the misappropriation of funds and segregation of duties.
• Related Party Transactions: Scrutinize the terms and pricing of transactions with the six primary Medical Corporations (MCs) and other related parties, given they constitute the vast majority of revenue.
• Fee Structure Changes: Monitor the financial impact of the upcoming fee structure revision for new clinics effective April 2025 and its effect on future revenue growth.
• Foreign Exchange Exposure: Assess the sensitivity of future earnings to fluctuations in the Japanese Yen, given the majority of operations are in Japan but reporting is in USD.
• Insurance Coverage: Review the extent of insurance coverage for product liability and medical accidents, as the company notes limited coverage in these areas.
• Life Insurance Gain: Confirm the realization of the expected $9.3 million gain from life insurance policy maturities in Q1 2025.